0001355250-12-000059.txt : 20121227 0001355250-12-000059.hdr.sgml : 20121227 20121227065610 ACCESSION NUMBER: 0001355250-12-000059 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121221 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20121227 DATE AS OF CHANGE: 20121227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellceutix CORP CENTRAL INDEX KEY: 0001355250 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134303398 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52321 FILM NUMBER: 121286219 BUSINESS ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: (978)-633-3623 MAIL ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: EconoShare, Inc. DATE OF NAME CHANGE: 20060306 8-K 1 reportcda_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report December 27, 2012

(Date of earliest event reported: December 21,  2012)

 

CELLCEUTIX CORPORATION

 

  

 

 

Nevada

 

30-0565645

 

 

 

(State or Other Jurisdiction of

 

(I.R.S. Employer

Incorporation or Organization)

 

Identification Number)

 

 

100 Cumming Center, Suite 151-B

Beverly, MA  01915

 

 

 

 (Address of principal executive offices and zip code)

 

(978)-236-8717

(Registrant's telephone number, including area code) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

o

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

o

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

o

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure

 

 

On December 21, 2012 the Company signed a Confidential Disclosure Agreement with one of the world’s most prominent cancer centers, located in the Southwest United States, who contacted Cellceutix indicating that they are interested in conducting studies of Kevetrin at their cancer center.  Furthermore, they informed us that they are prepared to fund the costs of these studies.   Although the Company believes that a full-fledged collaboration agreement will be signed in the very near term, as of the date of this report, such an agreement has not yet been executed.  There is therefore no assurance that such agreement will be executed.  

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  December 27, 2012

 

 

 

 

 

 

CELLCEUTIX CORPORATION

 

 

 

 

 

 

 

 

By:  

/s/ Leo Ehrlich

 

 

 

Chief Executive Officer